Table 1 Key characteristics of included case studies and trials
From: Evidencing the impact of cancer trials: insights from the 2014 UK Research Excellence Framework
Case studies (n = 46) | Number | Percentagec |
|---|---|---|
Research Excellence Framework (REF) impact typea | ||
 Health | 37 | 80% |
 Technological | 8 | 17% |
 Political | 1 | 2% |
REF Unit of Assessmentb | ||
 Clinical Medicine | 38 | 83% |
 Public Health, Health Services and Primary Care | 4 | 9% |
 Allied Health Professions, Dentistry, Nursing and Pharmacy | 2 | 4% |
 Psychology, Psychiatry and Neuroscience | 1 | 2% |
 Biological Sciences | 1 | 2% |
Trials (n = 110)d | ||
Trial focus | ||
 Treatment of cancer or its side effects | 97 | 88% |
 Screening | 6 | 5% |
 Diagnosis | 4 | 4% |
 Other (e.g. large observational trial to investigate cancer incidence) | 3 | 3% |
Phase of trial | ||
 I | 17 | 15% |
 II | 14 | 13% |
 III | 75 | 68% |
 Unknown/other | 4 | 4% |
Higher-education institution (n = 19) | ||
 University College London | 9 | 20% |
 Institute of Cancer Research | 4 | 9% |
 University of Leeds | 4 | 9% |
 University of Manchester | 4 | 9% |
 Queen Mary University of London | 4 | 9% |
 Imperial College London | 3 | 7% |
 University of Cardiff | 2 | 4% |
 University of Edinburgh | 2 | 4% |
 University of Glasgow | 2 | 4% |
 University of Nottingham | 2 | 4% |
 University of Oxford | 2 | 4% |
 University of Birmingham | 1 | 2% |
 University of Bradford | 1 | 2% |
 University of Bristol | 1 | 2% |
 Cardiff University | 1 | 2% |
 University of Cambridge | 1 | 2% |
 King’s College London | 1 | 2% |
 Newcastle University | 1 | 2% |
 University of Southampton | 1 | 2% |
Diagnoses of patients recruited to the included clinical trials (n = 110)d | ||
 Breast | 38 | 35% |
 Gastrointestinal (lower) | 15 | 14% |
 Haematological | 15 | 14% |
 Urological | 13 | 12% |
 Gynaecological | 10 | 9% |
 Thorax | 8 | 7% |
 Central nervous system | 4 | 4% |
 Head and neck (including thyroid) | 3 | 3% |
 Multiple cancer types | 3 | 3% |
 Gastrointestinal (upper) | 1 | 1% |
Main source of clinical trial funding (n = 110)d | ||
 Industry only | 33 | 30% |
 Charity and Research Council/Government/University | 19 | 17% |
 Research Council/Government/University only | 16 | 15% |
 Unknown | 14 | 13% |
 Charity and Industry | 13 | 12% |
 Charity, Industry and Research Council/Government/University | 8 | 7% |
 Charity only | 7 | 6% |